PDF(Pubmed)
Abstract：
Combining an immune checkpoint inhibitor with batiraxcept (AVB-S6-500), an AXL inhibitor that acts via selective binding to growth arrest-specific protein 6 (GAS6), may improve anti-tumor immunity in platinum-resistant ovarian cancer (PROC). This phase 1b trial of durvalumab in combination with escalating doses of batiraxcept enrolled patients with recurrent PROC (NCT04019288). The primary objective was to determine the toxicity profile of the combination. Eleven patients were enrolled on the trial. No dose-limiting toxicities were observed, and no objective responses were noted. Median progression free survival (PFS) was 1.81 months (95% confidence interval (CI) 1.71-2.40), and median overall survival (OS) was 4.53 months (95% CI 2.10-24.74). Batiraxcept effectively reduced serum GAS6 levels at 1-h post-treatment, resulting in trough levels below the limit of detection in all cases but one. In conclusion, the combination of batiraxcept and durvalumab was safe and tolerable but did not demonstrate anti-tumor activity in a heterogenous population of patients with recurrent PROC.
摘要：
结合免疫检查点抑制剂与batiraxcept（AVB-S6-500），一种通过选择性结合生长停滞特异性蛋白6（GAS6）起作用的AXL抑制剂，可能会提高铂耐药卵巢癌（PROC）的抗肿瘤免疫力。这项durvalumab联合递增剂量的batiraxcept的1b期试验纳入了复发性PROC患者(NCT04019288)。主要目的是确定组合的毒性特征。11名患者被纳入试验。没有观察到剂量限制性毒性，没有注意到客观的反应。中位无进展生存期（PFS）为1.81个月（95％置信区间（CI）1.71-2.40），中位总生存期（OS）为4.53个月（95％CI2.10-24.74）。Batiraxcept在治疗后1小时有效降低血清GAS6水平，导致波谷水平低于检测极限在所有情况下，除了一个。总之,batiraxcept和durvalumab的联合用药是安全且可耐受的,但在复发性PROC的异质性患者人群中未显示抗肿瘤活性.
